Oragenics Q3 2025 Shareholder Update
Oragenics Inc. (OGEN)
NASDAQ:AMEX Investor Relations:
ir.oragenics.com
Company Research
Source: Business Wire
Building on Solid Ground: From Vision to ExecutionRestoring Compliance, Advancing Innovation, Preparing for Clinical Milestones SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today reported key operational, financial, and strategic achievements for the third quarter of 2025. These milestones reflect the Company's evolution from vision to execution as it advances toward critical clinical trial initiation in Q4 2025/Q1 2026.OPERATIONAL EXCELLENCE: FOUNDATION RESTOREDNYSE American Compliance RegainedOn October 20, 2025, Oragenics regained full compliance with NYSE American's continued listing standards, resolving the stockholder equity deficiency that had placed the Company on noncompliant status. The below-compliance indicator has been removed, and Oragenics has been removed from the NYSE American noncompliant issuers roster."Regai
Show less
Read more
Impact Snapshot
Event Time:
OGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGEN alerts
High impacting Oragenics Inc. news events
Weekly update
A roundup of the hottest topics
OGEN
News
- Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity DeficiencyBusiness Wire
- Oragenics partners Receptor.AI for brain health candidate portfolio [Yahoo! Finance]Yahoo! Finance
- Oragenics announces partnership with Receptor.AI [Seeking Alpha]Seeking Alpha
- Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development [Yahoo! Finance]Yahoo! Finance
- Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline DevelopmentBusiness Wire
OGEN
Sec Filings
- 11/12/25 - Form 8-K
- 11/7/25 - Form 10-Q
- 10/21/25 - Form 8-K
- OGEN's page on the SEC website